HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration

Detalhes bibliográficos
Autor(a) principal: Jiamsakul, Awachana
Data de Publicação: 2017
Outros Autores: Kariminia, Azar, Althoff, Keri N., Cesar, Carina, Cortes, Claudia P., Davies, Mary-Ann, Viet Chau Do, Eley, Brian, Gill, John, Kumarasamy, Nagalingeswaran, Machado, Daisy Maria [UNIFESP], Moore, Richard, Prozesky, Hans, Zaniewski, Elizabeth, Law, Matthew
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: https://doi.org/10.1097/QAI.0000000000001499
https://repositorio.unifesp.br/handle/11600/58250
Resumo: Background: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups.
id UFSP_e9f85675c60157c8836f98d729ea53e4
oai_identifier_str oai:repositorio.unifesp.br/:11600/58250
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA CollaborationHIVsuppressionpaediatricsadultsIeDEABackground: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups.UNSW, Kirby Inst, Sydney, NSW 2052, AustraliaJohns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USAFdn Huesped, Buenos Aires, DF, ArgentinaUniv Chile, Sch Med, Santiago, ChileFdn Arriaran, Santiago, ChileUniv Cape Town, Sch Publ Hlth & Family Med, Cape Town, South AfricaChildrens Hosp 2, Ho Chi Minh City, VietnamUniv Cape Town, Dept Paediat & Child Hlth, Cape Town, South AfricaUniv Calgary, Calgary, AB, CanadaYRGCARE Med Ctr, Madras, Tamil Nadu, IndiaUniv Fed Sao Paulo, Pediat Infect Dis Div, Escola Paulista Med, Sao Paulo, BrazilJohns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USAUniv Stellenbosch, Dept Med, Div Infect Dis, Cape Town, South AfricaTygerberg Hosp, Cape Town, South AfricaUniv Bern, Inst Social & Prevent Med, Bern, SwitzerlandUniv Fed Sao Paulo, Pediat Infect Dis Div, Escola Paulista Med, Sao Paulo, BrazilWeb of ScienceU.S. National Institutes of Health's National Institute of Allergy and Infectious DiseasesEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Cancer InstituteCenters for Disease Control and Prevention, USAAgency for Healthcare Research and Quality, USAHealth Resources and Services Administration, USACanadian Institutes of Health Research, CanadaOntario Ministry of Health and Long Term CareGovernment of Alberta, CanadaIntramural Research Program of the National Cancer InstituteAustralian Government Department of Health and AgeingNCI: U01AI035004NCI: U01AI035039NCI: U01AI035040NCI: U01AI035041NCI: U01AI035042NCI: U01AI037613NCI: U01AI037984NCI: U01AI038855NCI: U01AI038858NCI: U01AI042590NCI: U01AI068634NCI: U01AI068636NCI: U01AI069432NCI: U01AI069434Centers for Disease Control and Prevention, USA: CDC-200-2006-18797Centers for Disease Control and Prevention, USA: CDC-200-2015-63931Agency for Healthcare Research and Quality, USA: 90047713Health Resources and Services Administration, USA: 90051652Canadian Institutes of Health Research, Canada: CBR-86906Canadian Institutes of Health Research, Canada: CBR-94036Canadian Institutes of Health Research, Canada: HCP-97105Canadian Institutes of Health Research, Canada: TGF-96118NCI: P30AI027757NCI: P30AI027763NCI: P30AI027767NCI: P30AI036219NCI: P30AI050410NCI: P30AI094189NCI: P30AI110527NCI: P30MH62246NCI: R01AA016893NCI: R01CA165937NCI: R01DA004334NCI: R01DA011602NCI: R01DA012568NCI: R24AI067039NCI: U01AA013566NCI: U01AA020790NCI: U01AI1031834NCI: U01AI034989NCI: U01AI034993NCI: U01AI034994NCI: M01RR000052NCI: U54MD007587NCI: UL1RR024131NCI: UL1TR000004NCI: UL1TR000083NCI: UL1TR000454NCI: UM1AI035043NCI: Z01CP010214NCI: Z01CP010176NCI: U01AI069907NCI: U01AI069923NCI: U01AI069924NCI: U01AI069918NCI: F31DA037788NCI: G12MD007583NCI: K01A1093197NCI: K23EY013707NCI: K24DA000432NCI: K24AI065298NCI: KL2TR000421NCI: N02CP055504NCI: U01AI103390NCI: U01AI103397NCI: U01AI103401NCI: U01AI103408NCI: U01DA036935NCI: U01HD032632NCI: U10EY008057NCI: U10EY008052NCI: U10EY008067NCI: U24AA020794Lippincott Williams & Wilkins2020-09-01T13:21:25Z2020-09-01T13:21:25Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion319-329https://doi.org/10.1097/QAI.0000000000001499Jaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017.10.1097/QAI.00000000000014991525-4135https://repositorio.unifesp.br/handle/11600/58250WOS:000416721800019engJaids-Journal Of Acquired Immune Deficiency SyndromesAustralasian HIV and AIDS ConferencePhiladelphiainfo:eu-repo/semantics/openAccessJiamsakul, AwachanaKariminia, AzarAlthoff, Keri N.Cesar, CarinaCortes, Claudia P.Davies, Mary-AnnViet Chau DoEley, BrianGill, JohnKumarasamy, NagalingeswaranMachado, Daisy Maria [UNIFESP]Moore, RichardProzesky, HansZaniewski, ElizabethLaw, Matthewreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2022-02-07T21:01:45Zoai:repositorio.unifesp.br/:11600/58250Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652022-02-07T21:01:45Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
title HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
spellingShingle HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
Jiamsakul, Awachana
HIV
suppression
paediatrics
adults
IeDEA
title_short HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
title_full HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
title_fullStr HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
title_full_unstemmed HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
title_sort HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
author Jiamsakul, Awachana
author_facet Jiamsakul, Awachana
Kariminia, Azar
Althoff, Keri N.
Cesar, Carina
Cortes, Claudia P.
Davies, Mary-Ann
Viet Chau Do
Eley, Brian
Gill, John
Kumarasamy, Nagalingeswaran
Machado, Daisy Maria [UNIFESP]
Moore, Richard
Prozesky, Hans
Zaniewski, Elizabeth
Law, Matthew
author_role author
author2 Kariminia, Azar
Althoff, Keri N.
Cesar, Carina
Cortes, Claudia P.
Davies, Mary-Ann
Viet Chau Do
Eley, Brian
Gill, John
Kumarasamy, Nagalingeswaran
Machado, Daisy Maria [UNIFESP]
Moore, Richard
Prozesky, Hans
Zaniewski, Elizabeth
Law, Matthew
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Jiamsakul, Awachana
Kariminia, Azar
Althoff, Keri N.
Cesar, Carina
Cortes, Claudia P.
Davies, Mary-Ann
Viet Chau Do
Eley, Brian
Gill, John
Kumarasamy, Nagalingeswaran
Machado, Daisy Maria [UNIFESP]
Moore, Richard
Prozesky, Hans
Zaniewski, Elizabeth
Law, Matthew
dc.subject.por.fl_str_mv HIV
suppression
paediatrics
adults
IeDEA
topic HIV
suppression
paediatrics
adults
IeDEA
description Background: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups.
publishDate 2017
dc.date.none.fl_str_mv 2017
2020-09-01T13:21:25Z
2020-09-01T13:21:25Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.1097/QAI.0000000000001499
Jaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017.
10.1097/QAI.0000000000001499
1525-4135
https://repositorio.unifesp.br/handle/11600/58250
WOS:000416721800019
url https://doi.org/10.1097/QAI.0000000000001499
https://repositorio.unifesp.br/handle/11600/58250
identifier_str_mv Jaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017.
10.1097/QAI.0000000000001499
1525-4135
WOS:000416721800019
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Jaids-Journal Of Acquired Immune Deficiency Syndromes
Australasian HIV and AIDS Conference
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 319-329
dc.coverage.none.fl_str_mv Philadelphia
dc.publisher.none.fl_str_mv Lippincott Williams & Wilkins
publisher.none.fl_str_mv Lippincott Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268401053335552